Formulary Search Results for: LENVATINIB
8.1.5 Other antineoplastic drugs - View Category
Total Formulary
LENVATINIB (Kisplyx) (capsules)
Restrictions:
Restricted to specialist use only in accordance with regional protocol for the following:
- Hepatocellular carcinoma: As monotherapy in adults with advanced or unresectable hepatocellular carcinoma who have recieved no prior systemic therapy. Please click here for regional protocol, NHS netwroks access required.
- Thyroid Carcinoma: Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI) - click here for regional protocol (NHS network access required)
- Renal Cell Carcinoma:
- In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior endothelial growth factor (VEGF)-targeted therapy. Click here for regional protocol (NHS network access required)
- Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment